← boardnext 2026-08-31next 2026-10-31
PRRUF
Immutep S.A.S.distress 1/10 · well-funded / low risk$0.050%today-84% from 52w high
Oncology 1
Lead: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$99M
Runway
—
Shares 1y
-52%
Price & events
-80.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
-80.0%
6M
-73.7%
1Y
-72.2%
2Y
-86.0%
5Y
-84.8%
All
Overview
- Market Cap
- $73.02M
- Enterprise Value
- $1.23M
- Volume
- 0
- 52 Week Range
- $0.04 – $0.32
- Total Shares
- 1.46B
- Float Shares
- 1.43B
- % Held by Insiders
- 3.02%
- % Held by Institutions
- 49.29%
- Beta
- 2.22
Pipeline stages · 2 programs
IMP761, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-31 Estimated 50% readout ~2026-09-30 | Phase 1 | IMP761, Placebo | Healthy | 79 | recruiting |
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 2/3 | eftilagimod alpha, Paclitaxel | Breast Carcinoma | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | active not recruiting |
| 2025-06 | Phase 1 | Eftilagimod Alpha, Paclitaxel | Metastatic Breast Cancer | 0 | withdrawn |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,460,389,575 · 0 offerings/1y · 0 PIPEs
- 2024-11-12SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- none identified
Recent news
- 2026-07-15Immutep Granted New US Patent for Cancer Treatment Methods - Moomoo
- 2026-07-14Immutep (IMMP) Secures New Patent for Cancer Treatment Innovatio - GuruFocus
- 2026-07-14Immutep (NASDAQ: IMMP) posts 30.9-month survival, reviews TACTI-004 trial - Stock Titan
- 2026-07-14Immutep Wins Fourth U.S. Patent for Key Cancer Immunotherapy Combination - TipRanks
- 2026-07-13Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial - Moomoo
- 2026-07-13Why Did Immutep (ASX: IMM) Jump 13.73%? - Kalkine
- 2026-07-13Health Check: Immutep shares bounce on revived lung cancer treatment hopes - Stockhead
- 2026-07-12Immutep Posts Strong NSCLC Survival Data as It Probes Phase III Setback - TipRanks
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.